MedWire News -- Study results demonstrate that genetic variation in the genes encoding angiotensin-II type 1 receptor (AGTR1) and bradykinin type 1 receptor (BDKRB1) significantly influences the treatment efficacy of the ACE inhibitor perindopril in patients with stable coronary artery disease (CAD).
